V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240012561 | 240008764 | null | 61.8 | Palliative (P) | 2019-05-01 | 2019-05-05 | Docetaxel+Gemcitabine (no prior RT) | N | N | 240015091 | TEMOZOLOMIDE |
| 240012562 | 240008764 | 1.55 | 112.7 | Curative (C) | 2019-04-05 | 2019-05-01 | Vincristine (weekly) | 02 | N | 240015091 | REMODL TRIAL |
| 240012563 | 240008764 | 1.54 | null | Curative (C) | 2018-04-10 | 2018-04-10 | DA-EPOCH-R | 02 | N | 240015091 | RUXOLITINIB |
| 240012564 | 240008765 | 1.71 | 50.3 | Curative (C) | null | 2016-06-01 | IVE | 2 | N | 240015211 | CARMUSTINE + THIOTEPA |
| 240012565 | 240012682 | 1.75 | 42.9 | Curative (C) | 2016-09-14 | 2016-09-14 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 2 | N | 240015306 | DARATUMUMAB |
| 240012566 | 240012683 | null | 84 | Palliative (P) | 2018-02-11 | 2018-02-23 | Cytarabine HD + Rituximab | N | N | 240015430 | R CODOX M |
| 240012567 | 240008768 | 1.8 | 50 | Curative (C) | 2016-10-18 | 2016-10-18 | BORTEZOMIB + RITUXIMAB | 02 | N | 240015434 | AML17 TRIAL |
| 240012568 | 240008769 | 1.66 | 51 | Disease modification (D) | 2015-07-07 | 2015-07-08 | REMODLB TRIAL | 02 | N | 240015521 | MPV |
| 240012569 | 240008771 | 1.65 | 53.4 | Palliative (P) | 2017-09-18 | 2017-09-23 | ICE-R | 02 | N | 240015633 | CARBOPLATIN + TOPOTECAN |
| 240012570 | 240008773 | 1.66 | 76.4 | Curative (C) | 2017-09-19 | 2017-09-19 | IVAC | N | N | 240015692 | DHAP - R |
| 240012571 | 240008775 | 1.63 | 60 | Unknown (U) | 2016-10-29 | 2016-10-29 | ICE-R | 02 | null | 240015871 | GALLIUM TRIAL |
| 240012572 | 240008775 | 1.83 | 93.7 | null | 2017-12-06 | 2017-12-21 | Capecitabine + Oxaliplatin 21day | null | null | 240015871 | CYTARABINE IT + METHOTREXATE |
| 240012573 | 240008776 | 1.87 | 67.6 | Curative (C) | 2017-08-20 | 2017-08-30 | IVE | N | N | 240016012 | ICE-R |
| 240012574 | 240015445 | null | null | Curative (C) | 2017-11-20 | 2017-12-20 | IMATINIB | N | N | 240016012 | CISPLATIN + FLUOROURACIL |
| 240012575 | 240008777 | 0 | 55.9 | Curative (C) | 2017-06-24 | 2017-07-15 | Carboplatin + Liposomal Doxorubicin | null | null | 240016111 | mEOC TRIAL |
| 240012576 | 240012690 | 1.71 | 75 | Curative (C) | 2016-11-09 | 2016-11-29 | DA-EPOCH-R | N | N | 240016330 | MITOXANTRONE |
| 240012577 | 240008783 | 1.7 | 73.5 | Curative (C) | 2016-08-23 | 2016-08-31 | CODOX M | N | N | 240016360 | ESHAP |
| 240012578 | 240012691 | 1.72 | 52.5 | Palliative (P) | 2017-12-02 | 2017-12-02 | Capecitabine + Oxaliplatin 21day | N | null | 240016360 | VEDEX |
| 240012579 | 240008784 | 1.62 | 51.3 | Palliative (P) | 2014-05-29 | 2014-05-29 | REMODLB TRIAL | 02 | N | 240016409 | CAV |
| 240012580 | 240008785 | 1.66 | null | Disease modification (D) | 2019-01-12 | 2019-01-12 | Temozolomide 150mg/m2 | 01 | N | 240016492 | AML19 TRIAL |
| 240012581 | 240008786 | 1.6 | 61 | Palliative (P) | 2014-12-25 | 2015-01-28 | Carboplatin + Vinorelbine Oral | Y | N | 240016504 | CYTARABINE INTRATHECAL |
| 240012582 | 240015923 | null | 45.5 | Palliative (P) | null | 2017-01-13 | Capecitabine + Oxaliplatin 21day | null | N | 240016513 | RUXOLITINIB |
| 240012583 | 240008787 | 1.76 | 72.6 | Palliative (P) | 2016-07-29 | 2016-08-11 | Gemcitabine + Oxaliplatin | N | N | 240016548 | CYTARABINE INTRATHECAL |
| 240012584 | 240015447 | 1.77 | 67 | Curative (C) | 2018-02-08 | 2018-02-15 | CARMUSTINE + THIOTEPA | 02 | N | 240016597 | OFATUMUMAB |
| 240012585 | 240015447 | 1.65 | null | Curative (C) | 2013-04-24 | 2013-05-23 | Ifosfamide | N | N | 240016597 | TRIPLE INTRATHECAL |
| 240012586 | 240008788 | 1.68 | 80.7 | Curative (C) | 2016-04-04 | 2016-04-04 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | N | N | 240017029 | CYTARABINE + RITUXIMAB |
| 240012587 | 240012695 | 0 | 90.7 | Palliative (P) | 2016-02-25 | 2016-02-25 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 02 | N | 240017071 | CYCLOPHOSPHAMIDE + VINBLASTINE |
| 240012588 | 240008791 | 1.81 | 67 | Disease modification (D) | 2017-01-19 | 2017-01-20 | Ofatumumab Monthly | N | N | 240017158 | GEMCITABINE + OXALIPLATIN + RITUXIMAB |
| 240012589 | 240012697 | 1.61 | 59.9 | Palliative (P) | 2017-12-17 | 2017-12-18 | VEDex | null | null | 240017201 | CARBOPLATIN + TOPOTECAN |
| 240012590 | 240008793 | 1.61 | 53.2 | Palliative (P) | null | 2017-04-22 | Topotecan (intravenous) | null | null | 240017222 | IMATINIB |
| 240012591 | 240012698 | 1.72 | 68.2 | Disease modification (D) | 2017-07-09 | 2017-07-19 | Temozolomide 200mg/m2 | 2 | N | 240017293 | CARMUSTINE + THIOTEPA |
| 240012592 | 240008797 | 1.6 | null | Palliative (P) | 2014-03-24 | 2014-03-27 | Bortezomib + Cyclophos + Dex | null | null | 240017472 | IVE |
| 240012593 | 240008797 | 1.83 | 0 | Palliative (P) | 2018-09-28 | 2018-12-29 | DA-EPOCH-R | Y | N | 240017472 | CARMUSTINE + THIOTEPA |
| 240012594 | 240008798 | 1.63 | null | Palliative (P) | 2016-09-10 | 2016-09-10 | Ifosfamide | N | Y | 240017540 | TRIFLURIDINE + TIPIRACIL |
| 240012595 | 240008798 | null | 80.1 | Disease modification (D) | null | 2016-07-05 | CISPLATIN + FLUOROURACIL | null | null | 240017540 | TOPOTECAN |
| 240012596 | 240015449 | 1.58 | 92.4 | Curative (C) | 2018-06-02 | 2018-06-03 | IVE | N | N | 240017652 | UKALL2014 |
| 240012597 | 240008799 | 1.8 | 81 | Curative (C) | 2018-01-18 | 2018-01-19 | Gemcitabine + Oxaliplatin | 2 | N | 240017716 | OFATUMUMAB |
| 240012598 | 240008803 | null | 91 | Curative (C) | null | 2017-12-23 | Triple / Double Intrathecal Therapy | N | N | 240017785 | CYTARABINE HD + METHOTREXATE HD |
| 240012599 | 240008805 | null | 60.4 | Palliative (P) | null | 2018-11-10 | CYTARABINE + METHOTREXATE + RITUXIMAB | N | N | 240017871 | IFOSFAMIDE |
| 240012600 | 240008806 | 1.52 | 50.9 | Not known (9) | 2016-07-22 | 2016-08-01 | CISPLATIN + FLUOROURACIL | N | N | 240018081 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 240012601 | 240008807 | 1.54 | 48.4 | Curative (C) | 2015-11-15 | 2017-05-30 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | N | N | 240018110 | DHAP - R |
| 240012602 | 240008808 | null | 58.75 | Curative (C) | 2014-06-27 | 2014-06-28 | Cytarabine+Methotrexate Intrathecal | N | N | 240018186 | CODOX M |
| 240012603 | 240008809 | 1.7 | 77 | Adjuvant (A) | 2017-09-04 | 2017-09-05 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | N | 240018242 | MABCUTE TRIAL |
| 240012604 | 240008810 | 1.73 | 0 | Not known (9) | 2014-08-22 | 2014-09-19 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | N | 240018318 | UKALL2014 |
| 240012605 | 240012705 | 1.64 | 55.9 | Palliative (P) | 2017-01-07 | 2017-01-27 | CODOX M | N | N | 240018318 | CAV |
| 240012606 | 240012705 | 1.79 | null | Disease modification (D) | 2014-10-27 | 2014-10-27 | CHOEP | N | N | 240018318 | CYTARABINE IT + METHOTREXATE |
| 240012607 | 240012705 | 1.73 | 84.3 | Curative (C) | 2017-07-28 | 2017-07-30 | CHLORAMBUCIL + OFATUMUMAB | 02 | N | 240018318 | R-EPOCH |
| 240012608 | 240008811 | 1.54 | null | Palliative (P) | null | 2018-10-28 | RUXOLITINIB | null | N | 240018610 | FBC |
| 240012609 | 240008811 | 1.61 | 72 | Curative (C) | 2016-07-12 | 2016-07-14 | ETOPOSIDE + IFOSFAMIDE | N | null | 240018610 | DACARBAZINE + DOXORUBICIN + VINBLASTINE |
| 240012610 | 240008811 | 1.63 | 91.4 | Palliative (P) | null | 2018-10-16 | RCEOP | N | N | 240018610 | DOCETAXEL + GEMCITABINE |